Business Context and Reporting Period
Company: Schering-Plough Corporation (Note: Metadata referenced Merck & Co., Inc., but the filing text is for Schering-Plough).
Reporting Period: Quarterly period ended June 30, 2005 (Form 10-Q).
Overview: Schering-Plough is a research-based pharmaceutical company operating in Prescription Pharmaceuticals, Consumer Health Care, and Animal Health segments. The company is currently executing a multi-year "Action Agenda" to stabilize finances following years of negative events, including an FDA consent decree regarding manufacturing practices and significant litigation investigations.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2005 |
Six Months Ended June 30, 2005 |
Six Months Ended June 30, 2004 |
|---|---|---|---|
| Net Sales | $2,532 million | $4,900 million | $4,110 million |
| Net Income/(Loss) | $(48) million | $78 million | $(138) million |
| Net Income/(Loss) Available to Common Shareholders | $(70) million | $35 million | $(138) million |
| Diluted EPS | $(0.05) | $0.02 | $(0.09) |
| Operating Cash Flow | N/A | $495 million | $333 million |
| Cash and Cash Equivalents (End of Period) | $4,134 million | $4,134 million | $4,155 million |
| Short-term Borrowings | $378 million | $378 million | $1,569 million |
| Long-term Debt | $2,392 million | $2,392 million | $2,392 million |
Margins: Cost of sales was 34.2% of net sales for the quarter and 35.8% for the six-month period. Selling, general, and administrative (SG&A) expenses were 44.1% and 44.8% respectively.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 18% ($385 million) for the quarter and 19% ($790 million) for the six-month period compared to 2004. Growth was driven by the Prescription Pharmaceuticals segment (up 20% and 22% respectively), including new sales from the Bayer agreement (AVELOX and CIPRO) and favorable foreign exchange rates.
- Profitability Turnaround: The company reported a net income of $78 million for the first six months of 2005, a significant improvement from a net loss of $138 million in the same period of 2004. This was largely due to higher equity income from the cholesterol joint venture with Merck.
- Special Charges: Special charges increased significantly to $259 million for the quarter and $286 million for the six months ended June 30, 2005, compared to $42 million and $112 million in 2004. The 2005 charges were primarily driven by a $250 million increase in litigation reserves related to the Massachusetts investigation.
- Equity Income: Equity income from the cholesterol joint venture (ZETIA/VYTORIN) rose to $170 million for the quarter and $389 million for the six months, compared to $77 million and $154 million in 2004.
- Debt Reduction: Short-term borrowings decreased from $1.569 billion at year-end 2004 to $378 million at June 30, 2005, reflecting the repayment of commercial paper.
Guidance, Outlook, and Risks
Management Commentary:
- Cash Flow Strategy: The company is repatriating foreign earnings under the American Jobs Creation Act of 2004 to fund U.S. cash needs, which have been negative. Management expects worldwide dividends and capital expenditures to exceed operating cash flow for the full year 2005.
- Product Outlook: Sales of PEG-INTRON in Japan benefited from "patient warehousing" in 2004/2005; comparisons in 2006 may be unfavorably impacted. The company expects R&D spending to increase in subsequent quarters.
- Strategic Alternatives: Management noted that if sufficient profit and cash flow cannot be achieved, the company may need to evaluate strategic alternatives. Contracts for key products (VYTORIN, ZETIA, REMICADE) contain change-of-control provisions.
Risks and Contingencies:
- Litigation: A $500 million reserve has been established for the Massachusetts investigation into sales, marketing, and pricing practices. The company warns that resolution could materially exceed this amount.
- Regulatory: The company is subject to an FDA consent decree requiring revalidation of manufacturing processes. Failure to meet deadlines could result in additional fines and production halts.
- Competition: Generic competition is increasing for products like REBETOL and ELOCON. The cholesterol market faces potential generic entry for competitors starting in 2006.
- Supply Chain: Manufacturing issues with a third-party supplier for an OTC product ($50 million annual sales) may impact supply in the near term.
Investor Verification Checklist
- Litigation Reserve Adequacy: Verify if the $500 million reserve for the Massachusetts investigation is sufficient given the scope of the DOJ and state inquiries.
- Cholesterol Joint Venture Performance: Monitor the sales trajectory of ZETIA and VYTORIN, as they are the primary drivers of equity income and future profitability.
- FDA Consent Decree Progress: Track the completion of cGMP Work Plans and revalidation programs to assess the risk of additional fines or production stoppages.
- Cash Repatriation Impact: Confirm the utilization of the $1.5 billion credit facility and the extent of foreign cash depletion due to repatriation under the American Jobs Creation Act.
- Generic Erosion: Assess the impact of generic competition on the REBETOL and ELOCON franchises in the coming quarters.